Known targets — ChEMBL curated mechanism
CHRM1CHRM2CHRM3CHRM4CHRM5SCN10ASCN11A
The experimentally established mechanism targets of Afacifenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.53 |
| ▸ | CHRM4 known ✓ | P08173 | 10/20 | 0.45 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afacifenacin SCHEMBL5099489 | 1.00 | CHRM3 (0.53) | CHRM3OPRM1CHRM4CHRM2CHRM1 | |
| Afacifenacin SCHEMBL29376782 | 1.00 | CHRM3 (0.53) | CHRM3OPRM1CHRM4CHRM2CHRM1 | |
| Afacifenacin SCHEMBL29537778 | 0.94 | CHRM3 (0.58) | CHRM3OPRM1CHRM4CHRM2CHRM1 | |
| Afacifenacin SCHEMBL1192029 | 0.94 | CHRM3 (0.58) | CHRM3OPRM1CHRM4CHRM2CHRM1 | |
| Afacifenacin SCHEMBL12229302 | 0.94 | CHRM3 (0.58) | CHRM3OPRM1CHRM4CHRM2CHRM1 | |
| SCHEMBL5103283 | 0.84 | CHRM3 (0.46) | CHRM3OPRM1CHRM2CCR8DRD2 | |
| SCHEMBL8569665 | 0.83 | CCR8 (0.46) | CHRM3OPRM1CHRM2CCR8DRD2 | |
| SCHEMBL8565700 | 0.83 | CHRM3 (0.56) | CHRM3OPRM1CHRM2CCR8CXCR3 | |
| SCHEMBL5100213 | 0.82 | CHRM3 (0.45) | CHRM3OPRM1CHRM2CCR8DRD2 | |
| SCHEMBL8571599 | 0.81 | CHRM3 (0.46) | CHRM3OPRM1CHRM2CCR8DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329665-B2 | E. g., (+)-3-{1-[3-(2,2,2-trifluoroethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4dihydro-2(1H)-quinazolinone; pollakiuria and urinary incontinence; anticholinergic agents; selective antagonism of the M3 muscarinic receptor which depresses frequency of rhythmic bladder contractions; side effects reduction | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-02-12 | — | — | US | claimed |
| EP-1424334-B1 | QUINAZOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-24 | — | — | EP | claimed |
| US-20050032819-A1 | Quinazolinone derivative | Sumitomo Pharma Co., Ltd. (JP) | 2005-02-10 | — | — | US | claimed |
| EP-1424334-A1 | QUINAZOLINONE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-06-02 | — | — | EP | claimed |
| US-7329665-B2 | E. g., (+)-3-{1-[3-(2,2,2-trifluoroethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4dihydro-2(1H)-quinazolinone; pollakiuria and urinary incontinence; anticholinergic agents; selective antagonism of the M3 muscarinic receptor which depresses frequency of rhythmic bladder contractions; side effects reduction | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-02-12 | — | — | US | disclosed |
| EP-1424334-B1 | QUINAZOLINONE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20050032819-A1 | Quinazolinone derivative | Sumitomo Pharma Co., Ltd. (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424334-A1 | QUINAZOLINONE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032819-A1 | Quinazolinone derivative | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885CHRM4 5/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.